Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas

Z. S. Pavletic, M. R. Bishop, Philip Jay Bierman, James Olen Armitage

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Until recently younger patients with B-cell chronic lymphocytic leukemia (CLL) have not been considered for treatment with high-dose therapy and bone marrow transplantation (BMT). Current results show that both autologous and allogeneic bone marrow transplantation can induce a high percentage of long lasting remissions in younger patients with poor-risk CLL. Because of the investigational character of BMT for CLL, all eligible patients should be enrolled in clinical trials. Autologous BMT or peripheral blood stem cell transplantation (PSCT) have become standard therapies for relapsed patients with Hodgkin's disease (HD) or intermediate- and high-grade non-Hodgkin's lymphoma (NHL). Data on autologous transplantation for low-grade NHL are not mature enough and more experience is needed in order to assess the long-term value of such approach. Ongoing studies of high-dose therapy in lymphomas are focused on performing BMT earlier in the course of the disease and exploring alternative sources of hematopoietic rescue such as allogeneic stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)118-124
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume50
Issue number3-4
DOIs
StatePublished - Jan 1 1996

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Autologous Transplantation
Peripheral Blood Stem Cell Transplantation
Homologous Transplantation
Stem Cell Transplantation
Therapeutics
Hodgkin Disease
Lymphoma
Clinical Trials

Keywords

  • bone marrow transplantation
  • chronic lymphocytic leukemia
  • lymphoma

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. / Pavletic, Z. S.; Bishop, M. R.; Bierman, Philip Jay; Armitage, James Olen.

In: Biomedicine and Pharmacotherapy, Vol. 50, No. 3-4, 01.01.1996, p. 118-124.

Research output: Contribution to journalArticle

@article{73affb1519634f438c48807074cb6b52,
title = "Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas",
abstract = "Until recently younger patients with B-cell chronic lymphocytic leukemia (CLL) have not been considered for treatment with high-dose therapy and bone marrow transplantation (BMT). Current results show that both autologous and allogeneic bone marrow transplantation can induce a high percentage of long lasting remissions in younger patients with poor-risk CLL. Because of the investigational character of BMT for CLL, all eligible patients should be enrolled in clinical trials. Autologous BMT or peripheral blood stem cell transplantation (PSCT) have become standard therapies for relapsed patients with Hodgkin's disease (HD) or intermediate- and high-grade non-Hodgkin's lymphoma (NHL). Data on autologous transplantation for low-grade NHL are not mature enough and more experience is needed in order to assess the long-term value of such approach. Ongoing studies of high-dose therapy in lymphomas are focused on performing BMT earlier in the course of the disease and exploring alternative sources of hematopoietic rescue such as allogeneic stem cell transplantation.",
keywords = "bone marrow transplantation, chronic lymphocytic leukemia, lymphoma",
author = "Pavletic, {Z. S.} and Bishop, {M. R.} and Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/0753-3322(96)85285-1",
language = "English (US)",
volume = "50",
pages = "118--124",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "3-4",

}

TY - JOUR

T1 - Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas

AU - Pavletic, Z. S.

AU - Bishop, M. R.

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Until recently younger patients with B-cell chronic lymphocytic leukemia (CLL) have not been considered for treatment with high-dose therapy and bone marrow transplantation (BMT). Current results show that both autologous and allogeneic bone marrow transplantation can induce a high percentage of long lasting remissions in younger patients with poor-risk CLL. Because of the investigational character of BMT for CLL, all eligible patients should be enrolled in clinical trials. Autologous BMT or peripheral blood stem cell transplantation (PSCT) have become standard therapies for relapsed patients with Hodgkin's disease (HD) or intermediate- and high-grade non-Hodgkin's lymphoma (NHL). Data on autologous transplantation for low-grade NHL are not mature enough and more experience is needed in order to assess the long-term value of such approach. Ongoing studies of high-dose therapy in lymphomas are focused on performing BMT earlier in the course of the disease and exploring alternative sources of hematopoietic rescue such as allogeneic stem cell transplantation.

AB - Until recently younger patients with B-cell chronic lymphocytic leukemia (CLL) have not been considered for treatment with high-dose therapy and bone marrow transplantation (BMT). Current results show that both autologous and allogeneic bone marrow transplantation can induce a high percentage of long lasting remissions in younger patients with poor-risk CLL. Because of the investigational character of BMT for CLL, all eligible patients should be enrolled in clinical trials. Autologous BMT or peripheral blood stem cell transplantation (PSCT) have become standard therapies for relapsed patients with Hodgkin's disease (HD) or intermediate- and high-grade non-Hodgkin's lymphoma (NHL). Data on autologous transplantation for low-grade NHL are not mature enough and more experience is needed in order to assess the long-term value of such approach. Ongoing studies of high-dose therapy in lymphomas are focused on performing BMT earlier in the course of the disease and exploring alternative sources of hematopoietic rescue such as allogeneic stem cell transplantation.

KW - bone marrow transplantation

KW - chronic lymphocytic leukemia

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0030006630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030006630&partnerID=8YFLogxK

U2 - 10.1016/0753-3322(96)85285-1

DO - 10.1016/0753-3322(96)85285-1

M3 - Article

VL - 50

SP - 118

EP - 124

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 3-4

ER -